Definium Therapeutics is trading at $34.36, up +4.22%, with the move appearing consistent with the biotech sector’s reported 2.09% rise.
- No clear new company-specific catalyst surfaced for October 20.
- Sector sentiment was supported by Merck KGaA’s planned $1.3 billion acquisition of Silence Therapeutics and anticipation around Moderna cancer-vaccine data.
- Definium’s positive Phase 3 results and analyst commentary were reported earlier and do not establish a fresh catalyst for this session.